Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Total Current Liabilities (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Total Current Liabilities for 2 consecutive years, with $28.6 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 30.71% to $28.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.6 million through Dec 2025, up 30.71% year-over-year, with the annual reading at $28.6 million for FY2025, 30.71% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $28.6 million at NRX Pharmaceuticals, down from $40.6 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $40.6 million in Q3 2025, with the low at $20.3 million in Q3 2024.